Benitec Biopharma Inc. (BNTC) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Benitec Biopharma Inc. (BNTC) stock forecast summary
Our AI scores Benitec Biopharma Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Benitec Biopharma Inc. is a small-cap company with a market capitalization of $293M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast. Its P/B Ratio of 1.65x is the lowest of the 43 peers that report one.
For BNTC, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -20.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -12.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.3%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, BNTC included.
BNTC price chart and AI forecast
How BNTC ranks among 4005 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Benitec Biopharma Inc. (BNTC) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | BNTC | Rank |
|---|---|---|
| Market Cap | $293M | 60/60 |
| P/B Ratio | 1.65x | 43/43 |
| EPS | $-0.98 | – |
| Book Value/Share | $5.23 | – |
Profitability & Margins
| Metric | BNTC | Rank |
|---|---|---|
| ROE | -25.7% | 30/38 |
| ROA | -24.9% | 35/42 |
| ROIC | -28.9% | 36/45 |
Financial Health
| Metric | BNTC | Rank |
|---|---|---|
| Current Ratio | 34.00x | 4/58 |
| D/E Ratio | 0.03x | 44/48 |
| Financial Leverage | 1.03x | 44/48 |
| Working Capital | $176M | 51/58 |
Cash Flow
| Metric | BNTC | Rank |
|---|---|---|
| Operating Cash Flow | -$17M | 39/59 |
Income Statement
| Metric | BNTC | Rank |
|---|---|---|
| Operating Income | -$51M | 31/51 |
| Net Income | -$46M | 27/46 |
| R&D Expense | $23M | 57/58 |
Dividend & Shareholder Information
| Metric | BNTC | Rank |
|---|---|---|
| Shares Outstanding | 34M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $182M | 99.3% of assets |
| Cash & Short-term Investments | $180M | 98.4% of assets |
| Total Liabilities | $6M | 3.1% of assets |
| Short-term Debt | $1M | 0.6% of assets |
BNTC quarterly financials and insider trading
Benitec Biopharma Inc. (BNTC) industry peers
Companies classified under the same SEC industry code as Benitec Biopharma Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| BNTC Benitec Biopharma Inc. | $293M | |
| LLY Eli Lilly & Co | $1.28T | |
| JNJ Johnson & Johnson | $655.56B | |
| ABBV Abbvie Inc. | $509.35B | |
| MRK Merck & Co., Inc. | $362.53B | |
| NVS Novartis Ag | $308.99B | |
| AZN Astrazeneca Plc | $289.62B | |
| ABT Abbott Laboratories | $197.53B | |
| NVO Novo Nordisk A S | $179.09B | |
| PFE Pfizer Inc | $170.31B | |
| VRTX Vertex Pharmaceuticals Inc / Ma | $137.50B | |
| BMY Bristol Myers Squibb Co | $129.04B | |
| SNY Sanofi | $115.65B | |
| GSK Gsk Plc | $101.70B | |
| REGN Regeneron Pharmaceuticals, Inc. | $92.96B | |
| TAK Takeda Pharmaceutical Co Ltd | $66.19B | |
| TEVA Teva Pharmaceutical Industries Ltd | $48.69B | |
| ONC Beone Medicines Ltd. | $44.02B | |
| ZTS Zoetis Inc. | $33.93B | |
| GMAB Genmab A/S | $33.93B | |
| RPRX Royalty Pharma Plc | $28.94B | |
| ROIV Roivant Sciences Ltd. | $26.45B | |
| UTHR United Therapeutics Corp | $24.26B | |
| INSM Insmed Inc | $23.86B | |
| VTRS Viatris Inc | $21.79B | |
| ALNY Alnylam Pharmaceuticals, Inc. | $20.98B | |
| ASND Ascendis Pharma A/S | $16.64B | |
| JAZZ Jazz Pharmaceuticals Plc | $14.76B | |
| BBIO Bridgebio Pharma, Inc. | $14.47B | |
| RDY Dr Reddys Laboratories Ltd | $12.13B | |
| ELAN Elanco Animal Health Inc | $11.83B | |
| SMMT Summit Therapeutics Inc. | $11.32B | |
| BMRN Biomarin Pharmaceutical Inc | $10.86B | |
| MDGL Madrigal Pharmaceuticals, Inc. | $9.24B | |
| TGTX Tg Therapeutics, Inc. | $9.20B | |
| PTGX Protagonist Therapeutics, Inc | $8.75B | |
| SYRE Spyre Therapeutics, Inc. | $8.52B | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.12B | |
| CORT Corcept Therapeutics Inc | $7.74B | |
| CYTK Cytokinetics Inc | $7.72B | |
| ALKS Alkermes Plc. | $7.47B | |
| PRAX Praxis Precision Medicines, Inc. | $7.33B | |
| ABVX Abivax S.A. | $7.32B | |
| RYTM Rhythm Pharmaceuticals, Inc. | $7.23B | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $6.94B | |
| AXSM Axsome Therapeutics, Inc. | $6.80B | |
| IONS Ionis Pharmaceuticals Inc | $6.45B | |
| ORKA Oruka Therapeutics, Inc. | $6.36B | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.21B | |
| MIRM Mirum Pharmaceuticals, Inc. | $6.07B | |
| LGND Ligand Pharmaceuticals Inc | $5.98B | |
| BLTE Belite Bio, Inc | $5.63B | |
| SUPN Supernus Pharmaceuticals, Inc. | $5.56B | |
| PTCT Ptc Therapeutics, Inc. | $5.49B | |
| MANE Veradermics, Inc | $5.37B | |
| COGT Cogent Biosciences, Inc. | $5.13B | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $4.64B | |
| ERAS Erasca, Inc. | $4.64B | |
| TVTX Travere Therapeutics, Inc. | $4.37B | |
| EWTX Edgewise Therapeutics, Inc. | $4.22B |
Where BNTC sits on the market map
Benitec Biopharma Inc. (BNTC) stock news
Loading...
Benitec Biopharma Inc. (BNTC) stock forecast FAQ
What is the Benitec Biopharma Inc. (BNTC) stock forecast?
Our AI scores Benitec Biopharma Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Benitec Biopharma Inc. stock predictions?
For BNTC, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -20.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -12.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Benitec Biopharma Inc. forecasts updated?
Benitec Biopharma Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Benitec Biopharma Inc.'s industry peers?
60 issuers in our coverage, BNTC included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.